Back to top
more

Novartis (NVS)

(Delayed Data from NYSE)

$118.50 USD

118.50
1,155,790

-2.39 (-1.98%)

Updated Sep 3, 2024 04:00 PM ET

After-Market: $118.50 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

AbbVie (ABBV) Provides Clinical Updates on Inflammatory Drugs

by Zacks Equity Research

AbbVie???s (ABBV) two studies evaluating Skyrizi in ulcerative colitis and Rinvoq in systemic lupus erythematosus meet their primary endpoints.

Incyte (INCY) Gets CRL for Jakafi Extended-Release Tablets

by Zacks Equity Research

The FDA issues a complete response letter to Incyte's (INCY) extended-release tablet formulation of Jakafi drug for the treatment of myelofibrosis, polycythemia vera and graft-versus-host disease.

Incyte (INCY) Receives FDA Approval for Skin Cancer Treatment

by Zacks Equity Research

Incyte (INCY) gets accelerated approval for retifanlimab-dlwr for the treatment of adults with metastatic or recurrent locally advanced merkel cell carcinoma.

Incyte (INCY) Vitiligo Drug Povorcitinib Positive in Phase II

by Zacks Equity Research

Incyte (INCY) announces positive data on povorcitinib and Opzelura for the treatment of nonsegmental vitiligo.

The Zacks Analyst Blog Highlights Johnson & Johnson, Toyota Motor, Infosys, Novartis and Equinix

by Zacks Equity Research

Johnson & Johnson, Toyota Motor, Infosys, Novartis and Equinix are part of the Zacks top Analyst Blog.

Novartis (NVS) Oncology Drug Gets FDA Nod for Label Expansion

by Zacks Equity Research

Novartis (NVS) obtains FDAs approval for the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) for pediatric brain cancer.

Sheraz Mian headshot

Top Stock Reports for Johnson & Johnson, Toyota Motor & Infosys

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Toyota Motor Corporation (TM) and Infosys Limited (INFY).

Novartis (NVS) Could Be a Great Choice

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.

Esperion Therapeutics (ESPR) Down 24% in a Week: Here's Why

by Zacks Equity Research

Shares of Esperion Therapeutics (ESPR) fell last week as the company's cardiovascular outcome CLEAR study results failed to meet investor expectations.

Zacks Industry Outlook Highlights J&J, Novo Nordisk, AstraZeneca, Novartis and Sanofi

by Zacks Equity Research

J&J, Novo Nordisk, AstraZeneca, Novartis and Sanofi have been highlighted in this Industry Outlook article.

Here's Why Novartis (NVS) is a Strong Value Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Kinjel Shah headshot

5 Large Drug Stocks to Watch as Sector Picks Up in 2023

by Kinjel Shah

Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, J&J (JNJ), Novo Nordisk (NVO), AstraZeneca (AZN), Novartis (NVS), and Sanofi (SNY) are worth retaining in your portfolio.

Lilly's (LLY) Verzenio Gets FDA Nod for Expanded Breast Cancer

by Zacks Equity Research

Eli Lilly (LLY) announces FDA approval of label expansion of Verzenio (abemaciclib), in combination with endocrine therapy, for treating HR+, HER2-, node-positive and high-risk early breast cancer.

Incyte (INCY) Discontinues Jakafi Combo Myelofibrosis Study

by Zacks Equity Research

Incyte (INCY) decides to scrap the LIMBER-304 study evaluating the efficacy and safety of parsaclisib plus Jakafi for myelofibrosis (MF) following an independent data monitoring committee recommendation.

Zacks.com featured highlights Sanofi, SK Telecom, PBF Energy, Arrow Electronics and Novartis

by Zacks Equity Research

Sanofi, SK Telecom, PBF Energy, Arrow Electronics and Novartis have been highlighted in this Screen of The Week article.

AstraZeneca (AZN) Enhertu Betters Outcomes in Multi-Tumor Study

by Zacks Equity Research

AstraZeneca (AZN) and Daiichi Sankyo' Enhertu met the pre-specified criteria for objective response rate and duration of response in the DESTINY-PanTumor02 phase II study.

Rajani Lohia headshot

These 5 Price-to-Sales Stocks Can Be Rewarding Investments

by Rajani Lohia

The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like SNY, SKM, PBF, ARW and NVS hold promise.

NVS vs. LLY: Which Stock Is the Better Value Option?

by Zacks Equity Research

NVS vs. LLY: Which Stock Is the Better Value Option?

After Plunging -7.17% in 4 Weeks, Here's Why the Trend Might Reverse for Novartis (NVS)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Novartis (NVS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Bayer's (BAYRY) Q4 Earnings and Revenues Top, Outlook Weak

by Zacks Equity Research

Bayer (BAYRY) beats on earnings and sales in the fourth quarter. However, its 2023 outlook is dismal.

Alnylam (ALNY) Q4 Earnings Top, Product Sales Boost Revenues

by Zacks Equity Research

Alnylam Pharmaceuticals (ALNY) reports better-than-expected fourth-quarter 2022 results. Total revenues of the company continue to be driven by the sales of Onpattro, Givlaari, Oxlumo and the newly approved Amvuttra.

Merck (MRK) Gets Priority Tag for Antiviral Drug Prevymis sNDA

by Zacks Equity Research

The FDA grants priority review designation to Merck's (MRK) sNDA seeking expanded use of Prevymis. The PDUFA date is Jun 5, 2023.

Incyte (INCY) Reports Positive Long-Term Data From HS Study

by Zacks Equity Research

Incyte's (INCY) povorcitinib shows sustained and durable efficacy across all treatment arms in the open-label extension period of the phase II HS study.

Gilead (GILD) Kite Reports Positive Data on CAR T-Cell Therapy

by Zacks Equity Research

Gilead (GILD) reports positive long-term results from the phase I/II study on Tecartus (brexucabtagene autoleucel) for acute lymphoblastic leukemia.

Novartis (NVS) Q4 Earnings Top, Revenues Miss Estimates

by Zacks Equity Research

Novartis (NVS) reports mixed fourth-quarter results, with key brands maintaining momentum but Cosentyx sales declining and generic competition remaining a drag.